MX337175B - Metodo para el tratamiento de disglicemia y oscilaciones en la glucosa. - Google Patents

Metodo para el tratamiento de disglicemia y oscilaciones en la glucosa.

Info

Publication number
MX337175B
MX337175B MX2011002227A MX2011002227A MX337175B MX 337175 B MX337175 B MX 337175B MX 2011002227 A MX2011002227 A MX 2011002227A MX 2011002227 A MX2011002227 A MX 2011002227A MX 337175 B MX337175 B MX 337175B
Authority
MX
Mexico
Prior art keywords
insulin
amphipathic
sensitizing
ionic compound
oral hypoglycemic
Prior art date
Application number
MX2011002227A
Other languages
English (en)
Other versions
MX2011002227A (es
Inventor
Alexander Macgregor
Original Assignee
Alexander Macgregor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexander Macgregor filed Critical Alexander Macgregor
Publication of MX2011002227A publication Critical patent/MX2011002227A/es
Publication of MX337175B publication Critical patent/MX337175B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas para reducir las oscilaciones en la glucosa en un sujeto normal o en un sujeto que tiene un trastorno relacionado con la insulina o disglicemia. La composición farmacéutica contiene una o más capas que contienen agente activo, las cuales contienen cada una, una mezcla mezclada en seco incluyendo una cantidad terapéuticamente efectiva de un agente hipoglicémico oral sensible a la insulina ionizable polar o una sal farmacéuticamente aceptable del mismo, y un compuesto anfipático en una forma monomélica que consiste de un compuesto iónico anfipático en forma monomélica. Cada mezcla mezclada en seco contiene una cantidad suficiente del compuesto jónico anfipático tal que al contacto con un fluido acuoso, el compuesto iónico anfipático forma un micelo inverso que comprende el agente hipoglicémico oral sensible a insulina ionizable polar. La presente invención también se refiere a un uso de una composición farmacéutica de liberación modificada que comprende una cantidad terapéuticamente efectiva de un agente hipoglicémico oral sensible a la insulina para sensibilizar los niveles de insulina pre-prandial (basal) y/o reducir las oscilaciones de glucosa postprandial en un paciente normal o en un paciente que tiene un trastorno relacionado con la insulina.
MX2011002227A 2008-08-29 2009-08-24 Metodo para el tratamiento de disglicemia y oscilaciones en la glucosa. MX337175B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002638240A CA2638240C (en) 2008-08-29 2008-08-29 Method of treating dysglycemia and glucose excursions
PCT/CA2009/001166 WO2010022497A1 (en) 2008-08-29 2009-08-24 Method of treating dysglycemia and glucose excursions

Publications (2)

Publication Number Publication Date
MX2011002227A MX2011002227A (es) 2011-07-29
MX337175B true MX337175B (es) 2016-02-15

Family

ID=40030453

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011002227A MX337175B (es) 2008-08-29 2009-08-24 Metodo para el tratamiento de disglicemia y oscilaciones en la glucosa.

Country Status (12)

Country Link
US (1) US9061061B2 (es)
EP (1) EP2231128B1 (es)
JP (2) JP2012500810A (es)
CN (1) CN101909604B (es)
AU (2) AU2009287368A1 (es)
BR (1) BRPI0917922A2 (es)
CA (1) CA2638240C (es)
ES (1) ES2708498T3 (es)
HR (1) HRP20190178T1 (es)
MX (1) MX337175B (es)
TR (1) TR201901238T4 (es)
WO (1) WO2010022497A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
AU2016351301B2 (en) * 2015-11-06 2022-08-04 Gelteq Pty Ltd Method and product for testing response to oral glucose load
CN110208705A (zh) * 2019-05-09 2019-09-06 赛尔网络有限公司 一种锂电池剩余寿命预测方法及装置
US20230402149A1 (en) * 2022-05-19 2023-12-14 Insulet Corporation Switching and customization of glucose prediction models in medicament delivery devices

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280423A (ja) * 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk 口腔内粘膜貼付剤
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
CA1337750C (en) 1987-11-24 1995-12-19 John L. Fulton Supercritical fluid reverse micelle separation
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
AU736951C (en) * 1998-03-19 2003-02-20 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6673612B2 (en) * 1999-07-16 2004-01-06 Mirus Corporation Micellar systems
US6086920A (en) * 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
ATE251449T1 (de) * 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
JP2003520759A (ja) * 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
ATE310507T1 (de) * 1999-12-28 2005-12-15 Ajinomoto Kk Orale zusammensetzungen für diabetes
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US6960357B2 (en) * 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
ITMI20011337A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
WO2003004009A1 (en) * 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
ITFI20010230A1 (it) 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
ATE424815T1 (de) * 2001-12-03 2009-03-15 Dor Biopharma Inc Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
CA2470636A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
US20030220301A1 (en) * 2002-02-14 2003-11-27 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US8323692B2 (en) * 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
ES2627842T3 (es) 2002-02-21 2017-07-31 Valeant Pharmaceuticals Luxembourg S.À.R.L. Formas de dosificación de liberación controlada
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
MXPA04012290A (es) 2002-06-07 2005-04-08 Univ Rutgers Formaciones de micela.
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
EP1562607A1 (en) * 2002-11-15 2005-08-17 Ranbaxy Laboratories, Ltd. Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
US20070219250A1 (en) * 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
JP2008516893A (ja) * 2004-08-27 2008-05-22 スフェリックス，インク． 多層錠剤および生体接着性剤形
US20090124702A1 (en) * 2005-01-25 2009-05-14 Pechetti Siva Satya Krishna Babu Pharmaceutical Compositions of Metformin
UY29445A1 (es) * 2005-03-30 2006-10-02 Generex Pharm Inc Composiciones para la transmisión transmucosa oral de la metformina
WO2006105659A1 (en) 2005-04-05 2006-10-12 Université de Montréal Hydrophilic core polymeric micelles for the delivery of water-soluble compounds
CN103271083B (zh) * 2005-10-07 2017-08-11 阿拉巴马大学 多功能离子液体组合物
US8414921B2 (en) * 2005-12-16 2013-04-09 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
EP2428205B1 (en) 2006-03-16 2012-10-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
DE102006027790A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Typ-2-Diabetes Kombinations-Wafer
WO2008013416A1 (en) * 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
RU2420268C2 (ru) * 2006-09-04 2011-06-10 Панацея Биотек Лимитед Способ программируемой плавучей доставки
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
EP2167048B1 (en) * 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
US20090186819A1 (en) * 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
WO2009080025A1 (en) 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising metformin
WO2009117130A2 (en) * 2008-03-21 2009-09-24 Mylan Pharmaceuticals, Inc. Extended release forumulation containing a wax
CA2638240C (en) 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions

Also Published As

Publication number Publication date
US20110159045A1 (en) 2011-06-30
MX2011002227A (es) 2011-07-29
WO2010022497A1 (en) 2010-03-04
CN101909604A (zh) 2010-12-08
AU2016228159A1 (en) 2016-10-06
EP2231128B1 (en) 2018-12-26
TR201901238T4 (tr) 2019-02-21
HRP20190178T1 (hr) 2019-05-03
EP2231128A4 (en) 2013-11-27
BRPI0917922A2 (pt) 2016-07-26
CN101909604B (zh) 2013-08-14
CA2638240C (en) 2010-02-02
JP2014159470A (ja) 2014-09-04
AU2016228159B2 (en) 2018-04-12
JP2012500810A (ja) 2012-01-12
US9061061B2 (en) 2015-06-23
EP2231128A1 (en) 2010-09-29
JP5902228B2 (ja) 2016-04-13
AU2009287368A2 (en) 2010-06-24
ES2708498T3 (es) 2019-04-09
AU2009287368A1 (en) 2010-03-04
CA2638240A1 (en) 2008-11-18

Similar Documents

Publication Publication Date Title
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
BR112014010275A2 (pt) formulações para tratamento de diabetes
ECSP088240A (es) Composición de trazodona para administración una vez por día
WO2010045656A3 (en) Novel sglt2 inhibitor dosage forms
NZ582049A (en) Transdermal delivery devices assuring an improved release of an active principle through a biological interface
JP2013505282A5 (es)
MX2008013828A (es) Combinacion farmaceutica que comprende 3-(3-dimetilanimo-1-etil-2- metil-propil)-fenol y un nsaid.
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
EA200901112A1 (ru) Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу
MX349176B (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
MX2009011900A (es) Curacion de herida diabetica.
IL197448A (en) Long-lasting glp-1 history of a drug used in the preparation of a hyperglycemia and diabetes drug
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
JP2016539921A5 (es)
CO6341514A2 (es) Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica
MX337175B (es) Metodo para el tratamiento de disglicemia y oscilaciones en la glucosa.
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида
MX2012000466A (es) Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal.
WO2010044582A3 (ko) Ｎ1-2-티오펜-2-일에틸-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
WO2007138233A3 (fr) Utilisation du zatosetron pour le traitement de la rosacee
WO2012096866A3 (en) Use of beta-adrenergic inverse agonists for smoking cessation

Legal Events

Date Code Title Description
FG Grant or registration